Open AccessDecreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine)
Author(s) -
Marina Ciomei,
Wilma Pastori,
Laura Capolongo,
Cristina Geroni,
G Melegaro,
Giulia Pennella,
Maria Grandi
Publication year - 1995
Publication title -
british journal of cancer
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/bjc.1995.537
Subject(s) - protein tyrosine phosphatase , phosphorylation , tyrosine , phosphatase , tyrosine kinase , tyrosine phosphorylation , cancer research , biology , phenotype , adenocarcinoma , ptpn11 , kinase , tyrosine kinase inhibitor , cytotoxic t cell , microbiology and biotechnology , in vitro , biochemistry , signal transduction , cancer , mutation , gene , genetics , kras
Resistance to FCE 24517 is not related to the emergence of any of the most frequently observed phenotypes. We have found that two resistant cell lines (L1210/24517 murine leukaemia and LoVo/24517 human colon adenocarcinoma) present congenital modifications in tyrosyl phosphatase and kinase activities. Moreover, the cytotoxic activity of FCE 24517 is increased in combination with a tyrosine phosphatase inhibitor and decreased in combination with protein kinase inhibitors, this being in agreement with the hypothesis that the activity of this drug is strictly dependent on the presence of tyrosine phosphorylated protein(s).